NDRA: ENDRA Company Value to Net Income

This price chart for ENDRA Life Sciences (NDRA) illustrates the business of a non-invasive liver analysis innovator utilizing the TAEUS method for the precise determination of hepatic steatosis via affordable ultrasound, where the indicator stands at -1.10. However, a lack of profitability and equipment registration complexities create serious financial threats. A slow start in device sales is temporarily increasing operating expenses, hindering the growth of software margins.

ENDRA Life Sciences develops innovative ultrasound systems whose commercial value depends on the integration of technologies into medical standards. The indicator is calculated as the ratio of market capitalization to net income, measuring the cost of one dollar of earnings. This metric reveals asset overvaluation during periods of inflationary pressure. The absence of stable flows makes data interpretation complex. By analyzing the current P/E ratio, an investor assesses market expectations for the future success of ENDRA Life Sciences.